推荐同事 机构合作 中文 繁體中文 English 한국어 日本語 Português Español

美国ACCDON公司旗下品牌

021-33361733，021-33632861

chinasupport@letpub.com

登录 注册 新注册优惠

CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS

2023年12月最新中科院分区表数据已经更新，欢迎查询！ 如果您对期刊系统有任何需求或者问题，欢迎点击此处反馈给我们。

按期刊名首写字母查看 CANCER BIOTHER 最新评论：网站进不去？ (2023-11-29)


期刊名:   ISSN:   研究方向:   影响因子: -   SCI收录:
大类学科:   小类学科:   中科院分区:   是否OA期刊:   结果排序:

按研究方向查看：


CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS期刊基本信息Hello，您是该期刊的第31119位访客


基本信息 登录收藏
期刊名字CANCER BIOTHERAPY AND RADIOPHARMACEUTICALSCANCER BIOTHERAPY AND RADIOPHARMACEUTICALS

CANCER BIOTHER RADIO
（此期刊被最新的JCR期刊SCIE收录）

LetPub评分
5.3
51人评分
我要评分

声誉
6.3

影响力
3.8

速度
8.6

期刊ISSN1084-9785
微信扫码收藏此期刊
E-ISSN1557-8852
2022-2023最新影响因子
（数据来源于搜索引擎）		3.4 点击查看影响因子趋势图
实时影响因子 截止2024年3月26日：2.639
2022-2023自引率2.90%点击查看自引率趋势图
五年影响因子3.1
h-index 55
CiteScore
CiteScoreSJRSNIPCiteScore排名
6.900.6500.650
学科分区排名百分位
大类：Medicine
小类：Radiology, Nuclear Medicine and Imaging		Q150 / 312
大类：Medicine
小类：Oncology		Q2100 / 366
大类：Medicine
小类：Pharmacology		Q289 / 301
大类：Medicine
小类：Cancer Research		Q289 / 214

期刊简介
Cancer Biotherapy and Radiopharmaceuticals is the established peer-reviewed journal, with over 25 years of cutting-edge content on innovative therapeutic investigations to ultimately improve cancer management. It is the only journal with the specific focus of cancer biotherapy and is inclusive of monoclonal antibodies, cytokine therapy, cancer gene therapy, cell-based therapies, and other forms of immunotherapies.

The Journal includes extensive reporting on advancements in radioimmunotherapy, and the use of radiopharmaceuticals and radiolabeled peptides for the development of new cancer treatments.
期刊官方网站http://www.liebertpub.com/overview/cancer-biotherapy-and-radiopharmaceuticals/8/
期刊投稿网址http://mc.manuscriptcentral.com/Cancerbiotherapy
期刊语言要求经LetPub语言功底雄厚的美籍native English speaker精心编辑的稿件，不仅能满足CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS的语言要求，还能让CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS编辑和审稿人得到更好的审稿体验，让稿件最大限度地被CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS编辑和审稿人充分理解和公正评估。LetPub的专业SCI论文编辑服务（包括SCI论文英语润色，同行资深专家修改润色，SCI论文专业翻译，SCI论文格式排版，专业学术制图等）帮助作者准备稿件，已助力全球15万+作者顺利发表论文。部分发表范例可查看：服务好评 论文致谢 。
提交文稿
是否OA开放访问No
通讯方式MARY ANN LIEBERT INC, 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, USA, NY, 10801
出版商Mary Ann Liebert Inc.
涉及的研究方向医学-核医学
出版国家或地区UNITED STATES
出版语言English
出版周期Bimonthly
出版年份1996
年文章数 46点击查看年文章数趋势图
Gold OA文章占比4.85%
研究类文章占比：
文章 ÷（文章 + 综述）		100.00%
WOS期刊SCI分区
（ 2022-2023年最新版）		WOS分区等级：2区

按学科分区JIF分区JIF排名JIF百分位
学科：MEDICINE, RESEARCH & EXPERIMENTAL
类别：SCIE		Q377/136
学科：ONCOLOGY
类别：SCIE		Q3125/241
学科：PHARMACOLOGY & PHARMACY
类别：SCIE		Q2126/277
学科：RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING
类别：SCIE		Q243/135
中科院《国际期刊预警
名单（试行）》名单 		2024年02月发布的2024版：不在预警名单中

2023年01月发布的2023版：不在预警名单中

2021年12月发布的2021版：不在预警名单中

2020年12月发布的2020版：不在预警名单中
中科院SCI期刊分区
（ 2023年12月最新升级版） 		点击查看中科院SCI期刊分区趋势图
大类学科小类学科Top期刊综述期刊
医学 4区4区4区
MEDICINE, RESEARCH & EXPERIMENTAL
医学：研究与实验		3区3区4区
ONCOLOGY
肿瘤学		3区3区4区
PHARMACOLOGY & PHARMACY
药学		2区1区4区
RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING
核医学		2区1区4区
否否
中科院SCI期刊分区
（ 2022年12月升级版）
大类学科小类学科Top期刊综述期刊
医学 2区4区4区
MEDICINE, RESEARCH & EXPERIMENTAL
医学：研究与实验		2区3区4区
ONCOLOGY
肿瘤学		2区4区4区
PHARMACOLOGY & PHARMACY
药学		1区4区4区
RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING
核医学		3区2区4区
否否
中科院SCI期刊分区
（ 2021年12月旧的升级版）
大类学科小类学科Top期刊综述期刊
医学 4区4区4区
MEDICINE, RESEARCH & EXPERIMENTAL
医学：研究与实验		4区2区4区
ONCOLOGY
肿瘤学		2区3区4区
PHARMACOLOGY & PHARMACY
药学		4区1区4区
RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING
核医学		3区2区4区
否否
SCI期刊收录coverage Science Citation Index Expanded (SCIE) (2020年1月，原SCI撤销合并入SCIE，统称SCIE)
Scopus (CiteScore)
PubMed Central (PMC)链接http://www.ncbi.nlm.nih.gov/nlmcatalog?term=1084-9785%5BISSN%5D
平均审稿速度网友分享经验：
平均3月
平均录用比例网友分享经验：
约95%
LetPub助力发表经LetPub编辑的稿件平均录用比例是未经润色的稿件的1.5倍，平均审稿时间缩短40%。众多作者在使用LetPub的专业SCI论文编辑服务（包括SCI论文英语润色，同行资深专家修改润色，SCI论文专业翻译，SCI论文格式排版，专业学术制图等）后论文在CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS顺利发表。
快看看作者怎么说吧：服务好评 论文致谢
期刊常用信息链接
同领域相关期刊 CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS期刊近年CiteScore指标趋势图
该杂志的自引率趋势图 CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS中科院SCI期刊分区趋势图
该杂志的年文章数趋势图 同领域作者分享投稿经验
CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS上中国学者近期发表的论文  
  • 同领域相关期刊
  • 期刊CiteScore趋势图
  • 期刊自引率趋势图
  • 中科院SCI期刊分区趋势图
  • 年文章数趋势图
  • 该期刊中国学者近期发表论文
  • 中科院SCI期刊分区相关期刊
  • 同类著名期刊名称 h-index CiteScore
    RADIOLOGY27134.20
    CLINICAL NUCLEAR MEDICINE532.60
    JOURNAL OF NUCLEAR MEDICINE19512.90
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING15314.20
    Radiologia Medica4111.10
    Circulation-Cardiovascular Imaging835.90
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS22811.00
    INVESTIGATIVE RADIOLOGY10313.60
    JOURNAL OF CARDIOVASCULAR MAGNETIC RESONANCE789.10
    EUROPEAN RADIOLOGY13411.10
    中科院SCI期刊分区同大类学科的热搜期刊 浏览次数
    MEDICINE618817
    BIOMATERIALS525887
    BIOMEDICINE & PHARMACOTHERAPY483610
    Journal of Materials Chemistry B469370
    Frontiers in Pharmacology465579
    Frontiers in Immunology438688
    JOURNAL OF ETHNOPHARMACOLOGY419084
    COLLOIDS AND SURFACES B-BIOINTERFACES412097
    Frontiers in Oncology396683
    COMPUTERS IN BIOLOGY AND MEDICINE391262
  •  

    CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS
    我来预测明年：
    稳步上升 表现平稳 逐渐下降　 刷新
  •  

    		  
  •  

    		  
  •  

    		  
  • 中国学者近期发表的论文
    1.Long Noncoding RNA Regulator of Reprogramming Regulates Cell Growth, Metastasis, and Cisplatin Resistance in Gastric Cancer via miR-519d-3p/HMGA2 Axis

    Author: Jin, Wenhua; Zhang, Hua; Li, Meng; Lin, Sen
    Journal: CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS. 2023; Vol. 38, Issue 2, pp. 122-131. DOI: 10.1089/cbr.2019.3525        PubMed      DOI
    2.LncRNA IUR Is Downregulated in Gastric Carcinoma and Associated with Poor Survival

    Author: Ou, Rui; Liu, Xin
    Journal: CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS. 2023; Vol. 38, Issue 2, pp. 116-121. DOI: 10.1089/cbr.2019.3436        PubMed      DOI
    3.Gene Silencing of Transcription Factor TEAD4 Inhibits Esophageal Cancer Cells by Regulating TCF7

    Author: He, Songlin; Gao, Ke; Mao, Long; Bhushan, Sandeep; Xiao, Zongwei
    Journal: CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS. 2023; Vol. 38, Issue 2, pp. 132-139. DOI: 10.1089/cbr.2020.3870        PubMed      DOI
    4.Survival Advantages in Gastric Cancer Patients Receiving Preoperative SOX Regimen Chemotherapy

    Author: Zhang, Qian; Zhang, Qinghua; Yan, Hui; You, Yanjie; Cao, Juan; Wang, Wenfan; Zhao, Dan; Zhang, Xiaoxu; Wu, Jing; Chen, Zhiqiang; Yang, Wenjun
    Journal: CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS. 2023; Vol. 38, Issue 2, pp. 81-88. DOI: 10.1089/cbr.2020.3970        PubMed      DOI
    5.Effect of Oral Nutritional Supplements on Patients with Esophageal Cancer During Radiotherapy

    Author: Yang, Liping; Gao, Jing; Zhou, Yan; Tao, Zhenchao; He, Jian; Yang, Jing; Wang, Ru; Zhang, Yangyang; Huang, Yifan; Zhou, Lingran; Sun, Bin
    Journal: CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS. 2023; Vol. 38, Issue 2, pp. 89-94. DOI: 10.1089/cbr.2020.3888        PubMed      DOI
    6.Circ_0003789 Facilitates Gastric Cancer Progression by Inducing the Epithelial-Mesenchymal Transition through the Wnt/beta-Catenin Signaling Pathway

    Author: Shao, Zhongbao; Yuan, Chang; Hu, Junbao; Wu, Yuli; Zeng, Chong
    Journal: CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS. 2023; Vol. 38, Issue 2, pp. 102-110. DOI: 10.1089/cbr.2020.4044        PubMed      DOI
    7.Diagnostic and Prognostic Value of Serum miR-296-5p and miR-28-3p in Human Gastric Cancer

    Author: Guo, Yuntong; Cui, Xiaolong; Zhang, Yu; Ma, Xiaobo; Ren, Aigang; Huang, He
    Journal: CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS. 2023; Vol. 38, Issue 2, pp. 95-101. DOI: 10.1089/cbr.2020.4144        PubMed      DOI
    8.Effects of Citrus aurantium L. on Gastrointestinal Motility and Gastric Cancer Cell Proliferation

    Author: Gao, Meng; Yang, Wuliang
    Journal: CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS. 2023; Vol. 38, Issue 2, pp. 111-115. DOI: 10.1089/cbr.2020.4267        PubMed      DOI
    9.Exosome-Mediated Transfer of circ-GLIS3 Enhances Temozolomide Resistance in Glioma Cells Through the miR-548m/MED31 Axis

    Author: Li, Guowei; Lan, Qing
    Journal: CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS. 2023; Vol. 38, Issue 1, pp. 62-73. DOI: 10.1089/cbr.2021.0299        PubMed      DOI
    10.A Novel Prognostic Biomarker CCR8 for Gastric Cancer and Anti-CCR8 Blockade Attenuate the Immunosuppressive Capacity of Tregs In Vitro

    Author: Zhang, Zhigang; Wang, Guoqing; Shao, Xiangyu; Wu, Hailu; Su, Xiangyu; Zhu, Long; Ji, Zhenling
    Journal: CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS. 2023; Vol. , Issue , pp. -. DOI: 10.1089/cbr.2022.0095        PubMed      DOI
  • 同大类学科的其他著名期刊名称 h-index CiteScore
    CA-A CANCER JOURNAL FOR CLINICIANS144642.90
    LANCET700133.20
    NEW ENGLAND JOURNAL OF MEDICINE933134.40
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION62245.40
    NATURE REVIEWS DRUG DISCOVERY289123.80
    BMJ-British Medical Journal015.30
    BMJ-British Medical Journal015.30
    NATURE REVIEWS IMMUNOLOGY35183.00
    NATURE MEDICINE497107.50
    Nature Reviews Disease Primers4860.90
    同分区等级的其他期刊名称 h-index CiteScore
    HARVARD BUSINESS REVIEW02.40
    QJM-AN INTERNATIONAL JOURNAL OF MEDICINE1086.10
    Energy Material Advances08.50
    CLINICAL AND EXPERIMENTAL HYPERTENSION453.60
    Journal of Public Transportation07.00
    Asian Journal of Psychiatry010.90
    Chinese Journal of Population Resources and Environment02.60
    VIEW08.60
    HLA933.00
    INTERNATIONAL JOURNAL OF SOCIAL PSYCHIATRY011.50


以上SCI期刊相关数据和信息来源于网络，仅供参考。
投稿状态统计： 我要评分：

    同领域作者分享投稿经验：共58条 （包含回复）

 我来分享

    联系我们 | 站点地图 | 友情链接 | 授权代理商 | 加入我们

    © 2010-2024 中国: LetPub上海分公司    网站备案号：沪ICP备10217908号-1    沪公网安备号：31010402006960

    增值电信业务经营许可证：沪B2-20211595

    礼翰商务信息咨询（上海）有限公司      办公地址：上海市徐汇区漕溪北路88号圣爱大厦1803室

    United States: Tel: 1-781-202-9968 Address: 400 5th Ave, Suite 530, Waltham, Massachusetts 02451